Ana SayfaEnglish NewsAstraZeneca will list shares directly in New York, but isn't leaving the...

AstraZeneca will list shares directly in New York, but isn’t leaving the UK

In order to attract küresel investors, AstraZeneca said it will directly list its ordinary shares on the New York Stock Exchange, in addition to its shares trading in the UK and Sweden.

To do so, the Anglo-Swedish pharmaceutical giant needs to replace its existing US listing of AstraZeneca American Depositary Receipts (ADRs) on the Nasdaq.

The company said that the move aims to harmonise its listing structure “while remaining headquartered in the UK”.

“The Board of AstraZeneca is recommending to shareholders a Harmonised Listing Structure for the Company’s ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange (NYSE),” the company said in a statement.

The announcement follows increased speculation that the pharma company may move its shares entirely from the London Stock Exchange, where it is one of the largest companies traded. And according to analysts, the current announcement doesn’t exclude this possibility in the future.

“While there is logic to shifting to a direct listing in the US rather than American Depositary Receipts beyond setting up for any longer-term moves, it does at least hint at the possibility of a more dramatic shift at some point in the future,” said AJ Bell investment director Russ Mould.  

The US has the world’s largest and most liquid public markets by capitalisation. A direct listing makes it easier for US investors to buy AstraZeneca shares directly without going through ADRs.

Compared to ordinary shares, American Depositary Receipts come with additional costs and extra steps. ADR investors may be subject to fees and double taxation, and ADRs come through a custodian bank.

“Enabling a küresel listing structure will allow us to reach a broader mix of küresel investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future,” said Michel Demaré, Chair of AstraZeneca.

In response to the announcement, AstraZeneca’s shares listed on the FTSE 100 rose 0.71% at around 11.30 CEST.


Quoted from Euronews.

RELATED ARTICLES

CEVAP VER

Lütfen yorumunuzu giriniz!
Lütfen isminizi buraya giriniz

- Reklam -
Link Kısaltma

Most Popular

Recent Comments

Güner türkyılmaz Açık Link Kısaltma Hakkında Kapsamlı Rehber
As.0102 Açık Linktree Alternatifi
Erkan ozguven Açık Linktree Alternatifi
Fadime Açık Linktree Alternatifi
Mert Açık Linktree Alternatifi
Sena karaca Açık Linktree Alternatifi
sevda Açık Linktree Alternatifi
sevda Açık Linktree Alternatifi
Dilek Açık Linktree Alternatifi
hnibrahim Açık Linktree Alternatifi
Mustafa Açık Linktree Alternatifi
Noortona Açık Linktree Alternatifi
Hakan Açık Linktree Alternatifi
Seda Açık Linktree Alternatifi
Hilal Açık Linktree Alternatifi
Cengiz Soğucaklı Açık Linktree Alternatifi
Mehtap Türkyılmaz Açık Linktree Alternatifi
Melek Arslan Açık Linktree Alternatifi
Burak demir Açık Linktree Alternatifi
Gsrg Açık Linktree Alternatifi
Murat Açık Linktree Alternatifi
Kerem Açık Linktree Alternatifi
Ahmet Aslan Açık Linktree Alternatifi
Murat Açık Linktree Alternatifi
Güner türkyılmaz Açık Linktree Alternatifi
Kerem Deren Açık Linktree Alternatifi
Furkan köse Açık Linktree Alternatifi